November 24, 2026

BSE Limited **Code: 532321**
P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited **Code: Zyduslife**
Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Sub.: **Incorporation of a wholly owned subsidiary in Australia**

Ref.: Intimation under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") read with SEBI Master Circular dated January 30, 2026 ("the SEBI Circular")

Dear Sir / Madam,

This is to inform that Zydus Lifesciences Limited has incorporated Zydus Australia Pty. Limited on November 24, 2026, as a wholly owned subsidiary in Australia to sell and distribute pharmaceutical products.

Requisite details as required to be disclosed pursuant to the provisions of regulation 30 of the Listing Regulations read with para A of part A of Schedule III of the Listing Regulations and para A(1)(1.1) of Annexure 18 of SEBI Master Circular are provided in **Annexure-"1"**.

Yours faithfully,
For, **Zydus Lifesciences Limited**

DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2026.11.24 11:20:48 +05'30'

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above

Annexure-"1"

Sr. No.	Particulars	Responses
1.	Name of the target entity, details in brief such as size, turnover etc.:	**Name of the Entity**: Zydus Australia Pty. Limited ("**ZAPL**") ZAPL is authorized to issue 1,00,000 equity shares of AUD 1/- per share. **Turnover:** Nil (as ZAPL is yet to commence business operations)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length":	Upon incorporation as a wholly owned subsidiary of the Company, ZAPL has become a related party of the Company. The Promoter / Promoter Group / Group Companies are not interested in the said incorporation.
3.	Industry to which the entity being acquired belongs:	Pharmaceutical
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	ZAPL shall be engaged to sell and distribute pharmaceutical products in Australia.
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	Not applicable
6.	Indicative time period for completion of the acquisition:	Not applicable

Sr. No.	Particulars	Responses
7.	Consideration-whether cash consideration or share swap or any other form and details of the same:	100% subscription to the paid-up share capital of ZAPL will be in cash.
8.	Cost of acquisition and/or the price at which the shares are acquired:	Not applicable
9.	Percentage of shareholding / control acquired and / or number of shares acquired:	100%
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	Not applicable

For, **Zydus Lifesciences Limited**

DHAVAL NARENDRA SONI

Digitally signed by DHAVAL NARENDRA SONI
Date: 2026.11.24 11:22:05 +05'30'

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063